Alemtuzumab

IgG4-related lymphadenopathy: case report

A 44-year-old man developed IgG4-related lymphadenopathy during treatment with alemtuzumab for multiple sclerosis [route, dosage and duration of treatment to reaction onset not stated].

The man, who had history of multiple sclerosis for more than 15 years, had been receiving alemtuzumab [Lemtrada]. Subsequently, he presented due to a left sided neck lump. CT/PET scan of lymph nodes revealed changes consistent with IgG4-related lymphadenopathy. Flow cytometry of lymph node tissue did not detect an aberrant T cell or monoclonal B cell populations. He had no other systemic manifestations of IgG4-related disease. Thus, IgG4-related lymphadenopathy associated with alemtuzumab was considered.

The man was thereafter treated with unspecified steroids [outcome not stated].

Tierney A, et al. IgG4-Related Disease as an Autoimmune Consequence of Alemtuzumab Therapy for Management of Multiple Sclerosis. Neurology 98 (Suppl.): No. 18, May 2022. Available from: URL: https://www.neurology.org/ [abstract]